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osting by EAbstract The objective of the current study was the development of a simple, precise and accurate
isocratic reversed-phase stability indicating Ultra Performance Liquid Chromatography [UPLC]
assay method and validated for determination of ticlopidine hydrochloride in solid pharmaceutical
dosage forms. Isocratic separation was achieved on a Zorbax SB-C18 (50 mm · 4.6 mm, 1.8 lm)
column using mobile phase of methanol–0.01 M ammonium acetate buffer, pH 5.0 (80:20, v/v) at
a ﬂow rate of 0.8 ml min1, the injection volume was 4.0 ll and the detection was carried out at
235 nm by using photo-diode array detector. The drug was subjected to oxidation, hydrolysis, pho-
tolysis and heat to apply stress condition. The method was validated for speciﬁcity, linearity, pre-
cision, accuracy, robustness and solution stability. The method was linear in the drug concentration
range of 62.5–375 lg ml1 with a correlation coefﬁcient of 0.9999. The precision (relative standard
deviation – RSD) of six samples was 1.31% for repeatability and the intermediate precision [RSD]
among six-sample preparation was 0.77%. The accuracy (recovery) was between 98.80% and
101.50%. Degradation products produced as a result of stress studies did not interfere with detec-
tion of ticlopidine hydrochloride and the assay can thus be considered stability indicating.
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lsevier1. Introduction
Stress testing is a part of development strategy under the Inter-
national Conference on Harmonization [ICH] requirements
and is carried out under more severe conditions than acceler-
ated conditions. These studies serve to give information on
drug’s inherent stability and help in the validation of analytical
methods to be used in stability studies (Bakshi and Singh,
2002, 2004; Bakshi et al., 2001; Pecanac et al., 2000). It is sug-
gested that stress testing should include the effect of tempera-
ture, light, oxidizing agents as well as susceptibility across a
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Cl
.
  HCl
Figure 1 Chemical structure of ticlopidine hydrochloride.
160 V. Ram et al.wide range of pH values. It is also recommended that analysis
of stability sample should de done through the use of a vali-
dated stability testing methods.
Ticlopidine hydrochloride is an inhibitor of platelet aggre-
gation used in the management and prevention of thromboem-
bolic disorders (Braunwald et al., 2008). Ticlopidine
hydrochloride is chemically named as: 5-[(2-chlorophenyl)
methyl]-4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochlo-
ride (Fig. 1). Its molecular formula is C14H14ClNSÆHCl having
molecular weight of 300.25 g mol1. It is used as adenosine
diphosphate [ADP] receptor antagonists in an antiplatelet
therapy (Papathanasiou et al., 2008). It is also signiﬁcantly re-
duces restenosis after endovascular therapy in femoropopliteal
lesions (Iida et al., 2008).
Quantitative methods for the determination of ticlopidine
in tablets using reﬂectance near-infrared and Fourier trans-
form Raman spectroscopy (Markopoulou et al., 2008). UPLC
coupled to electrospray tandem mass spectrometry was re-
ported (Borges et al., 2004; Rona et al., 1997). The UPLC
method has many advantages over reﬂectance near-infrared
and Fourier transform Raman spectroscopy method for quan-
titation. So far to our present knowledge, no validated stability
indicating UPLC assay method for the determination of ticlo-
pidine hydrochloride in pharmaceutical formulation was avail-
able in literature. Moreover UPLC method can be the ﬁrst
choice of chromatographers among the UPLC, reﬂectance
near-infrared and Fourier transform Raman spectroscopy
methods. So, development is based on UPLC method. This
paper deals with the forced degradation of ticlopidine hydro-
chloride under stress conditions like acid hydrolysis, base
hydrolysis and oxidation, thermal and photolytic stress. This
paper also deals with the validation of the developed method
for the assay of ticlopidine hydrochloride in its dosage form
(tablets).2. Experimental
2.1. Materials
Ticlopidine hydrochloride standard was provided by Aarti
Drugs Ltd., Boisar (India). Ticlopidine hydrochloride tablets
containing 250 mg ticlopidine hydrochloride and the inactive
ingredient used in drug matrix were obtained from (Trede
name: Ticlop, Manufactured by Vapi Care Pharma Pvt.
Ltd., Vapi, India) market. Analytical grade ammonium acetate
was purchased from Sisco Research Pvt. Ltd., Mumbai (In-
dia). UPLC grade methanol and water were obtained from
Spectrochem Pvt. Ltd., Mumbai (India). Analytical grade
hydrochloric acid, glacial acetic acid, sodium hydroxide pelletsand 30% (v/v) hydrogen peroxide solution were obtained from
Ranbaxy Fine Chemicals, New Delhi (India).
2.2. Instrumentation
The LC system of Waters Acquity UPLC with Photo diode ar-
ray detector was used for this study and chromatographic sep-
aration was achieved on Zorbax SB-C18 (50 mm · 4.6 mm,
1.8 lm) column as stationary phase with binary gradient
mode.
2.3. Chromatographic conditions
Chromatographic analysis was performed on Zorbax SB-C18
(50 mm · 4.6 mm, 1.8 lm) column. The mobile phase con-
sisted of methanol–0.01 M ammonium acetate buffer pH 5.0
(80:20, v/v). To prepare the buffer solution, 0.7708 g ammo-
nium acetate was weighed and dissolved in 1000 ml HPLC
grade water and then adjusted to pH 5.0 with glacial acetic
acid. Mobile phase was ﬁltered through a 0.20 lm nylon mem-
brane (Millipore Pvt. Ltd., Bangalore, India) and degassed in
an ultrasonic bath (Spincotech Pvt. Ltd., Mumbai). The ﬂow
rate of the mobile phase was adjusted to 0.8 ml min1 and
the injection volume was 4.0 ll. Detection was performed at
235 nm.
2.4. Standard preparation
A ticlopidine hydrochloride standard solution containing
250 lg ml1 was prepared in a 100 ml volumetric ﬂask by dis-
solving 25.00 mg of ticlopidine hydrochloride and then diluted
to volume with methanol as diluents.
2.5. Tablet sample preparation
The whole 20 tablets had to be crushed together and ﬁnely
powdered. Then a deﬁnite weight of the powder can be taken
for further manipulation. From these, 1444.0 mg powder was
weighed and transferred into a 500 ml volumetric ﬂask. About
50 ml methanol was added and sonicated for a minimum
30 min. with intermittent shaking. Then content was brought
back to room temperature and diluted to volume with metha-
nol. The sample was ﬁltered through 0.22 lm nylon syringe ﬁl-
ter. The concentration obtained was 250 lg ml1 of ticlopidine
hydrochloride.
2.6. Method validation
2.6.1. Speciﬁcity study
The speciﬁcity of the method was determined by checking the
interference of placebo with analyte which was eluted by
checking the peak purity of ticlopidine hydrochloride during
the force degradation study. The peak purity of the ticlopidine
hydrochloride was found satisfactory under different stress
conditions.
2.6.1.1. Design of the force degradation study. The degradation
samples were prepared by transferring powdered tablets,
equivalent to 250 mg ticlopidine hydrochloride into a 250 ml
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acidic, alkaline and oxidant media and also for thermal and
photolytic conditions. After the degradation treatments were
completed, the stress content solutions were allowed to equili-
brate to room temperature and diluted with mobile phase to
attain 250 lg ml1 concentrations. Speciﬁc conditions were de-
scribed as follows.
2.6.1.1.1. Acidic degradation condition. Acidic degradation
study was performed by heating the drug content in 0.1 N
HCl at 80 C for 2.0 h and mixture was neutralized.
2.6.1.1.2. Alkali degradation condition. Alkaline degrada-
tion study was performed by heating the drug content in
1 M NaOH at 80 C for 2 h and mixture was neutralized.
2.6.1.1.3. Oxidative degradation condition. Oxidation degra-
dation study was performed by heating the drug content in 3%
(v/v) H2O2 at 80 C for 1 h.
2.6.1.1.4. Thermal degradation condition. Thermal degrada-
tion was performed by exposing solid drug at 80 C for 72 h.
Ticlopidine hydrochloride is found to be stable under thermal
degradation condition.
2.6.1.1.5. Photolytic degradation condition. Photolytic deg-
radation study was performed by exposing the drug content
in UV-light for 72 h.
2.6.2. Linearity
Five points calibration curve was obtained in a concentration
range from 62.5 to 375 lg ml1 for ticlopidine hydrochloride.
2.6.3. Precision
The precision of the assay method was evaluated in terms of
repeatability by carrying out six independent assays of test sam-
ple preparation and the % RSD of assay (intraday) was calcu-
lated. Intermediate precision of the method was checked by
performing the same procedure on the different day (interday)
by another person under the same experimental condition.
2.6.4. Accuracy
An accuracy study was performed by adding known
amounts of ticlopidine hydrochloride to the placebo prepara-
tion. The actual and measured concentrations were com-
pared. Recovery of the method was evaluated at three
different concentration levels (corresponding to 50%, 100%
and 150% of test preparation concentration). For each
concentration level, three sets were prepared and injected
in duplicate.
2.6.5. Robustness
The robustness of study was carried out to evaluate the inﬂu-
ence of small but deliberate variations in the chromatographic
conditions. The factors chosen for this study were the ﬂow rate
(±0.1 ml min1), mobile phase composition [0.01 M ammo-
nium acetate buffer pH 5.0–acetonitrile (78:22 and 82:18, v/
v)], buffer pH (±0.2 pH) and using different lot of LC column.
2.6.6. Solution stability
The stability of solution for test preparation was evaluated.
The solution was stored at ambient temperature and 2–5 C
and tested at interval of 12, 24, 36 and 48 h. The responses
for the aged solution were evaluated using a freshly prepared
standard solution.3. Results and discussion
3.1. Development and optimization of the HPLC method
Proper selection of the methods depends upon the nature of
the sample (ionic or ionisable or neutral molecule) its molecu-
lar weight and solubility. Ticlopidine hydrochloride dissolves
in polar solvent thus RP-UPLC was selected to estimate them.
To develop a rugged and suitable UPLC method for the quan-
titative determination of ticlopidine hydrochloride, the analyt-
ical conditions were selected after testing the different
parameters such as diluents, buffer, buffer concentration, or-
ganic solvent for mobile phase and mobile phase composition
and other chromatographic conditions. Our preliminary trials
using different composition of mobile phases consisting of
water with methanol or acetonitrile, did not give good peak
shape.
The mobile phase consisted of methanol–0.01 M ammo-
nium acetate buffer pH 5.0 (80:20, v/v). By using 0.01 M
ammonium acetate buffer in 1000 ml of buffer, adjusted to
pH 5.0 with glacial acetic acid and keeping mobile phase com-
position as methanol–ammonium acetate buffer (80:20, v/v),
best peak shape was obtained. For the selection of organic
constituent of mobile phase, methanol was chosen to reduce
the longer retention time and to attain good peak shape.
Fig. 2(A) and (B) represent the chromatograms of standard
and test preparation, respectively.
3.2. System suitability
A system suitability test of the chromatographic system was
performed before each validation run. Five replicate injections
of standard preparation were injected and asymmetry, theoret-
ical plate and % RSD of peak area were determined for same.
For all system suitability injections, asymmetry was less than
2.0, theoretical plates were greater than 10,000 and % RSD
of peak area less than 2.0 was found.
3.3. Speciﬁcity
The speciﬁcity of the method was determined by checking the
interference of placebo with analyte and the proposed method
was eluted by checking the peak purity of ticlopidine hydro-
chloride during the force degradation study. The peak purity
of the ticlopidine hydrochloride was found satisfactory under
different stress conditions. There was no interference of any
peak of degradation products with the drug peak. Major deg-
radation was found in the oxidative condition and that prod-
uct was degraded up to 7.0–8.0%. The major impurity peaks
were found at 9.01 min (Fig. 2(C)). In alkali degradation, it
was found that around 5–6% of the drug degraded
(Fig. 2(D)) and in photolytic condition around 4–5% of the
drug degraded. Ticlopidine hydrochloride was found to be
slightly degraded in acidic while it was stable under the thermal
degradation.
3.4. Linearity
Five points calibration curve was obtained in a concentration
range from 62.5 to 375 lg ml1 for ticlopidine hydrochloride.
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Figure 2 (A) Chromatogram of standard preparation; (b) chromatogram of test preparation; (c) chromatogram of oxidative forced
degradation study; (d) chromatogram of alkali forced degradation study.
162 V. Ram et al.The response of the drug was found to be linear in the investi-
gation concentration range and the linear regression equationwas y = 7165671.78378x  34207.26 with correlation coefﬁ-
cient 0.9999.
Table 1 Evaluation data of precision study.
Set Intraday (n= 6) Interday (n= 6)
1 101.4 100.2
2 98.8 99.3
3 101.6 98.3
4 99.4 99.7
5 101.5 100.3
6 99.2 100.2
Mean 100.3 99.7
Standard deviation 1.31 0.77
% RSD 1.31 0.77
Table 2 Evaluation data of accuracy study.
Concen-
tration
(%)
Amount added
concentrationa
(mg/ml)
Amount found
concentrationa
(mg/ml)
% Recovery %
RSD
50 0.1227 0.1207 98.37 0.27
100 0.2513 0.2499 99.45 0.22
150 0.3713 0.3759 101.22 0.87
a Each value corresponds to the mean of three determinations.
Table 3 Evaluation data of solution stability study.
Intervals % Assay for
test preparation solution
stored at 2–5 C
% Assay for test
preparation solution stored
at ambient temperature
Initial 100.2 101.0
12 h 101.1 101.7
24 h 98.5 99.8
36 h 99.6 99.3
48 h ± SD 98.6 ± 1.10 98.4 ± 1.32
Table 4 Evaluation data of robustness study.
Robust conditions % Assay System suitability parameters
Theoretical
plates
Asymmetry
Flow 0.7 ml/min 98.2 10,244 1.08
Flow 0.9 ml/min 98.8 10,365 1.18
Buﬀer pH 4.8 100.3 10,400 1.10
Buﬀer pH 5.2 100.5 10,388 1.20
Buﬀer–ACN (78:22, v/v) 98.4 10,354 1.09
Buﬀer–ACN (82:18, v/v) 100.7 10,300 1.15
Column change diﬀerent
lot No. Zorbax SB-C18
(50 mm · 4.6 mm, 1.8 lm)
99.7 10,270 1.12
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The results of repeatability and intermediate precision study are
shown in Table 1. The developed method was found to be pre-
cise as the % RSD values for the repeatability and intermediate
precision studies were <1.31% and <0.77%, respectively,
which conﬁrm that the method was precise.3.6. Accuracy
The UPLC area responses for accuracy determination are de-
picted in Table 2. The results show that best recoveries
(98.80% and 101.50%) of the drug were obtained at each
added concentration, indicating that the method was accurate.
3.7. Solution stability study
Table 3 shows the results obtained in the solution stability
study at different time intervals for test preparation. It was
concluded that the test preparation solution was found stable
up to 48 h at 2–5 C and was ambient temperature as during
this time the result was not decreased below the minimum
percentage.
3.8. Robustness
The result of robustness study of the developed assay method
was established in Table 4. The result shows that during all
variance conditions, assay value of the test preparation solu-
tion was not affected and it was in accordance with that of
the actual. System suitability parameters were also found sat-
isfactory; hence the analytical method would be concluded as
robust.
4. Conclusion
A new stability-indicating UPLC method has been developed
to be routinely applied to determine ticlopidine hydrochloride
in pharmaceutical dosage form. The method was validated by
employment of ICH recommended stress condition. The meth-
od has been proved to be speciﬁc, linear, precise, accurate and
robust and stability indicating. Hence, the method is recom-
mended for routine quality control analysis and also stability
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